Sirtuin 1-Peroxisome proliferator-activated receptor gamma coactivator 1-alpha pathway (SIRT1-PGC-1α pathway) (SIRT1-PGC-1α pathway)

The Sirtuin 1-Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (SIRT1-PGC-1α) pathway is a fundamental regulatory axis that couples cellular energy status with mitochondrial function and metabolic adaptation (NIH, 2025). SIRT1, a nicotinamide adenine dinucleotide (NAD+)-dependent deacetylase, serves as a metabolic sensor that directly deacetylates and activates PGC-1α, a master coactivator of mitochondrial biogenesis and oxidative metabolism (ResearchGate, 2015; NIH, 2019). This interaction is often part of a larger AMPK/SIRT1/PGC-1α signaling network that responds to energetic stress, such as exercise or caloric restriction, to enhance ATP production and antioxidant defenses (ResearchGate, 2025; Consensus, 2024). Dysregulation of this pathway is a hallmark of various pathologies, including type 2 diabetes, obesity, and neurodegenerative diseases like Alzheimer's and Parkinson's, where mitochondrial decline is a primary driver (NIH, 2025; ResearchGate, 2011). Therapeutic strategies targeting this pathway primarily focus on SIRT1 activators, such as resveratrol and SRT1720, or NAD+ boosters to restore mitochondrial health and metabolic homeostasis (NIH, 2019; ResearchGate, 2025). However, the broad regulatory reach of SIRT1 across multiple cellular processes necessitates careful consideration of tissue-specific effects and potential off-target interactions with other substrates like p53 (NIH, 2011; NIH, 2025).

Other names

SIRT1/PGC-1α axisAMPK/SIRT1/PGC-1α pathwaySirtuin 1-PGC-1α signalingSIRT1-PGC-1α regulatory axisSirtuin 1-Peroxisome proliferator-activated receptor gamma coactivator 1-alpha pathway

SIRT1-mediated deacetylation and activation of PGC-1α, which subsequently co-activates transcription factors to drive mitochondrial gene expression and metabolic adaptation (NIH, 2025; ResearchGate, 2025).